Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type
Valneva SE EU:VLA Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.062 1.09% 5.74 5.67 5.938 6.036 5.468 5.50 708,988 02:01:45

Valneva Shares Climb as Pfizer Takes $95 Million Stake

20/06/2022 9:07am

Dow Jones News


Valneva (EU:VLA)
Historical Stock Chart


From Mar 2022 to Sep 2022

Click Here for more Valneva Charts.

By Joshua Kirby

 

Shares in French drugmaker Valneva SE trade sharply higher Monday after U.S. peer Pfizer Inc. agreed to take a shareholding in the company, as the pair look to boost their development of a vaccine against Lyme disease.

Under the agreement, Pfizer will invest 90.5 million euros ($95 million) in an 8.1% stake in Valneva via a reserved capital increase at a price of EUR9.49 a share, the two companies said Monday, adding that the investment will close Wednesday.

The deal aims to support the partnership between the two companies in developing a vaccine candidate, known as VLA15, against Lyme disease, they said.

At 0727 GMT, shares were trading 17% higher at EUR9.30.

The move could herald a takeover of Valneva by the larger company, according to Jean-Jacques Le Fur, an analyst with Bryan Garnier. If an imminent Phase 3 trial proves successful, "it is logical to think that this first move could have in mind a takeover of Valneva," Mr. Le Fur said in a research note following the news.

Valneva will use the funds from the equity investment to support its contribution to Pfizer's Phase-3 development of VLA15, which should begin in the third quarter this year, the companies said.

As part of the investment deal, the companies also amended the VLA15 collaboration and licensing agreement, with Valneva now to fund 40% of remaining shared development costs, compared with 30% in the initial agreement.

Pfizer will meanwhile now pay Valneva tiered royalties ranging from 14% to 22%, compared with royalties starting at 19% in the initial agreement. On top of these royalties, Pfizer will pay up to $100 million in milestones based on cumulative sales. Other development and early commercialization milestones are unchanged, the companies said, adding that $168 million of these latter payments remain, including a $25 million payment to Valneva upon Pfizer's initiation of the Phase 3 study.

A license application for VLA15 could come as early as 2025, depending on the success of the Phase 3 study, the companies said.

 

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

 

(END) Dow Jones Newswires

June 20, 2022 03:52 ET (07:52 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Valneva Chart

1 Year Valneva Chart

1 Month Valneva Chart

1 Month Valneva Chart
ADVFN Advertorial
Your Recent History
EU
VLA
Valneva
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220927 04:02:04